Study Stopped
The study run its course
Ultrasound Detection and Characterization of Subclinical Hypertrophy in Diabetes
Ultrasound Guided Detection and Characterization of Subclinical Lipohypertrophy in Type 1 and Type 2 Diabetes Mellitus
1 other identifier
observational
100
1 country
1
Brief Summary
This is a pilot study to enroll 100 people to assess the incidence of lipohypertrophy as detected with ultrasound and its impact on glycemic variability.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2015
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 21, 2015
CompletedFirst Posted
Study publicly available on registry
January 28, 2015
CompletedStudy Start
First participant enrolled
March 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 8, 2021
CompletedResults Posted
Study results publicly available
April 4, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
April 22, 2025
CompletedMay 7, 2025
April 1, 2025
5.9 years
January 21, 2015
May 16, 2022
April 29, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of Participants With Presence of Subclinical Lipohypertrophy
Lipohypertrophy seen on ultrasound but not felt by palpation
Assessed one time only at the time of clinic visit
Interventions
Abdomen scanned with portable ultrasound to determine presence of subclinical lipohypertrophy.
Eligibility Criteria
People age 19 and over with type 1 or type 2 diabetes who take insulin to manage their diabetes.
You may qualify if:
- years of age or older
- Type 1 or Type 2 diabetes
- Using insulin to manage diabetes for at least 2 years
You may not qualify if:
- Using insulin pumps, insulin secretagogues, Glucagon-Like Peptide-1 (GLP-1) agonists to manage diabetes
- Use of immunosuppressant agents
- Women who are pregnant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Vancouver General Hospital
Vancouver, British Columbia, V5Z 1M9, Canada
Related Publications (1)
Kapeluto JE, Paty BW, Chang SD, Meneilly GS. Ultrasound detection of insulin-induced lipohypertrophy in Type 1 and Type 2 diabetes. Diabet Med. 2018 Oct;35(10):1383-1390. doi: 10.1111/dme.13764. Epub 2018 Jul 16.
PMID: 29908078DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Mr Boris Feldman, Research Associate
- Organization
- Gerontology Research Lab
Study Officials
- PRINCIPAL INVESTIGATOR
Graydon Meneilly, MD
University of British Columbia
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor, UBC Department of Medicine
Study Record Dates
First Submitted
January 21, 2015
First Posted
January 28, 2015
Study Start
March 1, 2015
Primary Completion
February 8, 2021
Study Completion
April 22, 2025
Last Updated
May 7, 2025
Results First Posted
April 4, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share